Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus aureus Infection

ABSTRACT Daptomycin is a lipopeptide antibiotic with activity against gram-positive bacteria, including Staphylococcus aureus. We defined the pharmacodynamic parameters that determine the activity of daptomycin for S. aureus using in vitro methods and the Craig (W. A. Craig, J. Redington, and S. C. Ebert, J. Antimicrob. Chemother. 27[Suppl. C]:29–40, 1991) neutropenic mouse thigh infection model. In Mueller-Hinton broth, the MICs for threeS. aureus isolates were 0.1 to 0.2 μg/ml. In mouse serum, the MICs were 1.0 μg/ml. The protein binding of daptomycin was 90 to 92.5% in mouse serum. Single-dose intraperitoneal (i.p.) pharmacokinetic studies with infected mice showed a linear relationship between dose versus the maximum concentration of drug in serum and dose versus the area under the concentration-time curve (AUC). The serum half-life of daptomycin in infected mice was approximately 1.8 h. In single-dose, dose-ranging studies using mice, daptomycin showed a dose-response effect described by an inhibitory sigmoidEmax (maximum effect) curve (r = 0.974; P ≪ 0.001). The density of S. aureus in untreated controls was 8.26 log10 CFU/g, and the Emax was 3.97 log10 CFU/g. The 50% effective dose (ED50) was 3.7 mg/kg of body weight i.p. and the stasis dose was 7.1 mg/kg. Dose fractionation studies at schedules of Q6h, Q12h, and Q24h, for total 24-h ED30, ED60, and ED80 doses of 2.5, 5.6, and 15 mg/kg i.p., showed no difference in effect at each total 24-h dose level by schedule, indicating that the AUC/MIC ratio is the dynamically linked variable.

[1]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[2]  W. Alborn,et al.  Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032 , 1987, Antimicrobial Agents and Chemotherapy.

[3]  G. Eliopoulos,et al.  In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic , 1986, Antimicrobial Agents and Chemotherapy.

[4]  J. Bilello,et al.  Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy , 1994, Antimicrobial Agents and Chemotherapy.

[5]  Y. Fukuchi,et al.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.

[6]  I. L. Smith,et al.  Role for dual individualization with cefmenoxime. , 1984, The American journal of medicine.

[7]  G. Drusano,et al.  Daptomycin: a novel agent for Gram-positive infections. , 1999, Expert opinion on investigational drugs.

[8]  A. Gerber,et al.  Constant infusions vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro. , 1982, The Journal of infectious diseases.

[9]  P. Huovinen,et al.  In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria , 1987, Antimicrobial Agents and Chemotherapy.

[10]  U. Flückiger,et al.  Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model , 1991, Antimicrobial Agents and Chemotherapy.

[11]  G. Drusano Role of pharmacokinetics in the outcome of infections , 1988, Antimicrobial Agents and Chemotherapy.

[12]  G. Drusano,et al.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis , 1993, Antimicrobial Agents and Chemotherapy.

[13]  W. Alborn,et al.  Daptomycin disrupts membrane potential in growing Staphylococcus aureus , 1991, Antimicrobial Agents and Chemotherapy.

[14]  H. Akaike A new look at the statistical model identification , 1974 .

[15]  I. Bakker-Woudenberg,et al.  Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats , 1986, Antimicrobial Agents and Chemotherapy.

[16]  F. Lowy Staphylococcus aureus infections. , 2009, The New England journal of medicine.

[17]  B. Brenner,et al.  Glomerular actions of angiotensin II. , 1984, The American journal of medicine.

[18]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[19]  N. Melchior,et al.  In-vitro evaluation of ampicillin/brobactam and comparison with other beta-lactam antibiotics. , 1991, The Journal of antimicrobial chemotherapy.

[20]  R. Smith,et al.  Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. , 1993, Chemotherapy.

[21]  G. Bodey,et al.  A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. , 1979, The American journal of medicine.

[22]  W. Craig,et al.  Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. , 1991, The Journal of antimicrobial chemotherapy.

[23]  M. Sachdeva,et al.  Effect of protein binding of daptomycin on MIC and antibacterial activity , 1991, Antimicrobial Agents and Chemotherapy.

[24]  F. Tenover,et al.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.

[25]  W. Craig,et al.  Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. , 1990, Scandinavian journal of infectious diseases. Supplementum.

[26]  R. Stern,et al.  Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. , 1983, The Journal of infectious diseases.

[27]  J. Turnidge,et al.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.

[28]  H. Black,et al.  Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers , 1992, Antimicrobial Agents and Chemotherapy.

[29]  E. Bingen,et al.  Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. , 1990, The Journal of antimicrobial chemotherapy.

[30]  G L Drusano,et al.  Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. , 1998, JAMA.

[31]  J A Bilello,et al.  Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies , 1994, Antimicrobial Agents and Chemotherapy.

[32]  J. Waitz Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[33]  Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. , 1997, MMWR. Morbidity and mortality weekly report.

[34]  J J Schentag,et al.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.

[35]  R. Gaynes,et al.  An overview of nosocomial infections, including the role of the microbiology laboratory , 1993, Clinical Microbiology Reviews.

[36]  R. Moore,et al.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. , 1987, The Journal of infectious diseases.